The present results indicate that pemigatinib may have anti-cancer activity in other solid tumors bearing certain FGFR point mutations other than FGFR2 fusion/rearrangement-positive CCA as approved by the regulatory in multiple regions. Here, FGFR2 is linked to cancer.